Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company suffered a setback when the FDA issued a complete response letter to the supplemental new drug application for Nuplazid for treating dementia-related psychosis. Acadia resubmitted the supplemental new drug application to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. Notably, several additional studies on Nuplazid n targeting different CNS indications, such as'dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 19 September 2026
2019-09-11 09:31:00 Wednesday ET
Central banks in India, Thailand, and New Zealand lower their interest rates in a defensive response to the Federal Reserve recent rate cut. The central ban
2019-10-17 08:35:00 Thursday ET
The European Central Bank expects to further reduce negative interest rates with new quantitative government bond purchases. The ECB commits to further cutt
2024-05-27 03:23:34 Monday ET
Stock Synopsis: Life insurers emphasize profit margins over sales growth rates. We review and analyze the recent market share data in the U.S. life insur
2018-09-30 14:34:00 Sunday ET
Goldman, JPMorgan, Bank of America, Credit Suisse, Morgan Stanley, and UBS face an antitrust lawsuit. In this lawsuit, a U.S. judge alleges the illegal cons
2022-02-02 10:33:00 Wednesday ET
Our proprietary alpha investment model outperforms most stock market indices from 2017 to 2022. As of early-January 2023, the U.S. Patent and Trademark O
2018-01-15 07:35:00 Monday ET
Treasury Secretary Steven Mnuchin welcomes a weak U.S. dollar amid pervasive fears of an open trade war between America and China. At the World Economic For
Reports
Metrics
Events
AI Stock Synopses